Let’s talk about how Mobetron will be the advantage in your facility’s comprehensive strategy in treating breast cancer.
Single-Fraction APBI with Mobetron
You likely already know that electron-beam IORT has been successfully treating multiple cancer indications for nearly 50 years and has been treating breast cancer since the early 1990’s. The first accelerated partial breast irradiation (APBI) treatment with the IntraOp® Mobetron® was performed in 2006. Today, more than 20,000 women have been treated with electron IORT demonstrating equivalency in local control with reduced toxicity and improved cosmesis. More than 10,000 breast cancer patients have been treated with the Mobetron.
The ASTRO Consensus removes experimental status and recognizes the single fraction electron-beam IORT modality
ASTRO Distinguishes Mobetron Over Other Modalities
The American Society of Radiation Oncology (ASTRO) issued an updated Consensus Statement on Accelerated Partial Breast Irradiation (APBI) in the journal Practical Radiation Oncology confirming the use of electron-beam IORT as an effective modality for the treatment of suitable patients with invasive breast cancer.
Furthermore, the Consensus removes experimental status and recognizes the single fraction electron-beam IORT modality, validating Mobetron and distinguishing it from all other IORT treatment options available in the fight against cancer.
The milestone distinguishes the Mobetron from all other IORT treatment options and further validates that as few as two (2) minutes of precision targeted electron beam treatment with the Mobetron can replace six weeks of conventional, post-operative external beam x-ray radiation of the entire breast. For qualified patients with breast cancer this means faster treatment, faster recovery and significantly fewer side effects, as non-involved tissue is spared.
Citing the current status of the TARGIT trial, the ASTRO Consensus Statement recommended that “low-energy x-ray IORT should continue to be used within the context of a prospective registry or clinical trial to ensure long-term local control and toxicity outcomes are prospectively monitored.”
The new APBI Consensus Statement published by ASTRO is a clinically meaningful step forward in the validation of partial breast radiotherapy for selected patients with early stage breast cancer. At Stanford, we have been pioneering APBI using single-fraction IORT for over 15 years and can attest to the favorable results not only from an oncological perspective but also in terms of quality of life for our patients.”
Publications For Single-Fraction APBI
These findings support the recent guidelines from the American Society for Radiation Oncology (ASTRO) supporting the use of electron IORT for low-risk patients.Read More
Recently, interest has also grown in intraoperative radiation therapy (IORT), which treats the partial breast with a single dose of radiation using either low-energy x-rays or electrons, most commonly delivered at the time of surgery. These different modalities are likely to have certain tradeoffs with regard to their effectiveness and toxicity profiles, although these tradeoffs have yet to be completely described in the existing literature.Read More
“Accelerated Partial Breast Irradiation Using Only Intraoperative Electron Radiation Therapy in Early Stage Breast Cancer.”
APBI using a single dose of IOERT can be delivered safely in women with early, low-risk breast cancer in carefully selected patients.Read More
APBI And Oncoplastic Surgery With Mobetron
More and more oncological breast surgeons are utilizing classical plastic surgery techniques to provide their patients with not just favorable oncological results but also excellent cosmetic results. It may already be a core focus in your treatment protocol because patient demand for oncoplastic surgery has grown dramatically.
Gone are the days when reconstructive surgery needed to be completed in a separate surgical procedure after radiation therapy and the breast healed. Accelerated Partial Breast Irradiation with IORT spares healthy tissue from avoidable radiation in Whole Breast Irradiation and reduces treatment time from as many as thirty treatments to one.
Mobetron is highly conducive to oncoplastic techniques. This enables hospitals and physicians to be more productive and provides women who elect to have APBI with Mobetron the opportunity to also have oncoplastic reconstruction during the same procedure, allowing them to complete all surgery and radiation treatment in a single day, and with minimal complications.
Mobetron Single Fraction APBI vs. Typical Treatment
The Mobetron Advantage
Enables flexible movement within and between OR suites
Eliminates costly construction and retrofitting
Published evidence complemented by expert opinion
Proven efficacy in multiple cancer indications
Electron-beam IORT delivers radiation to only involved tissue
Treatment in minutes facilitates more procedures
Bottom-Line Productivity In The OR With Mobetron
Mobetron delivers significantly better productivity compared to traditional external-beam radiation treatments. In calculating Mobetron’s efficiency gains in Facilities and Personnel, less is more. The portable, self-shielded design of Mobetron requires absolutely no costly bunker construction or facility retrofitting. Its soft-docking laser-alignment system gets surgical teams working quickly. And two-minute integrated treatment times equate to more procedures during the course of each daily unit.
These are bold claims. But oncologists who use Mobetron know that precision in dose and volume and uniformity in dosimetry are vital in the operating room. Combine that with shorter treatment cycles and minimized impact to healthy tissue, and Mobetron is an effective, productive, and safe solution. We have the numbers to prove it.
The IntraOp Mobetron delivers significantly better productivity compared to traditional external-beam radiation treatments.
Taking The Next Step In Breast Cancer Treatment
At IntraOp, we are driven by innovations that can win the battle against cancer. Now we know more is possible with Mobetron. The world’s best oncologists tell us it’s a necessary component in their toolkit. Healthcare executives tell us Mobetron is a magnet for attracting new patients and the world’s greatest oncological talent. With Mobetron, we’re accelerating the cure.Learn More about the Mobetron